MARKET

ZBIO

ZBIO

Zenas BioPharma Inc.
NASDAQ
35.07
-0.74
-2.07%
After Hours: 35.07 0 0.00% 16:10 12/18 EST
OPEN
36.64
PREV CLOSE
35.81
HIGH
37.93
LOW
34.48
VOLUME
321.88K
TURNOVER
--
52 WEEK HIGH
41.50
52 WEEK LOW
5.83
MARKET CAP
1.88B
P/E (TTM)
-2.7685
1D
5D
1M
3M
1Y
5Y
1D
Evercore ISI Sticks to Their Buy Rating for Zenas BioPharma, Inc. (ZBIO)
TipRanks · 1d ago
Orelabrutinib’s SLE Phase 2b Success Could Be A Game Changer For Zenas BioPharma (ZBIO)
Simply Wall St · 1d ago
Zenas BioPharma rises 10.6%
TipRanks · 2d ago
Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside
TipRanks · 2d ago
Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential
TipRanks · 2d ago
Zenas BioPharma (ZBIO): Reassessing a Rich Valuation After Positive Orelabrutinib Lupus Trial Milestones
Simply Wall St · 2d ago
Zenas BioPharma Approves 2026 Inducement Plan
TipRanks · 3d ago
Zenas Biopharma Approves 2026 Inducement Plan for New Hires
Reuters · 3d ago
More
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

Webull offers Zenas BioPharma Inc. stock information, including NASDAQ: ZBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZBIO stock methods without spending real money on the virtual paper trading platform.